593 related articles for article (PubMed ID: 23098998)
41. Activation of the fibrinolytic system.
Robison AK; Collen D
Cardiol Clin; 1987 Feb; 5(1):13-9. PubMed ID: 3103919
[TBL] [Abstract][Full Text] [Related]
42. Tissue-type plasminogen activator-binding RNA aptamers inhibiting low-density lipoprotein receptor family-mediated internalisation.
Bjerregaard N; Bøtkjær KA; Helsen N; Andreasen PA; Dupont DM
Thromb Haemost; 2015 Jul; 114(1):139-49. PubMed ID: 25855589
[TBL] [Abstract][Full Text] [Related]
43. Effects of colloid and crystalloid solutions on endogenous activation of fibrinolysis and resistance of polymerized fibrin to recombinant tissue plasminogen activator added ex vivo.
Mittermayr M; Streif W; Haas T; Fries D; Velik-Salchner C; Klingler A; Innerhofer P
Br J Anaesth; 2008 Mar; 100(3):307-14. PubMed ID: 18158312
[TBL] [Abstract][Full Text] [Related]
44. Differential fibrinolytic properties of the recombinant plasminogen activator BM 06.022 in human plasma and blood clot systems in vitro.
Martin U; Sponer G; Strein K
Blood Coagul Fibrinolysis; 1993 Apr; 4(2):235-42. PubMed ID: 8388740
[TBL] [Abstract][Full Text] [Related]
45. Human thrombin and calcium bound factor Xa significantly shorten tPA-induced fibrin clot lysis time via neutralization of plasminogen activator inhibitor type 1 activity.
Urano T; Nagai N; Matsuura M; Ihara H; Takada Y; Takada A
Thromb Haemost; 1998 Jul; 80(1):161-6. PubMed ID: 9684803
[TBL] [Abstract][Full Text] [Related]
46. Cleavage of surfactant-incorporating fibrin by different fibrinolytic agents. Kinetics of lysis and rescue of surface activity.
Günther A; Markart P; Kalinowski M; Ruppert C; Grimminger F; Seeger W
Am J Respir Cell Mol Biol; 1999 Dec; 21(6):738-45. PubMed ID: 10572071
[TBL] [Abstract][Full Text] [Related]
47. Soluble fibrin degradation products potentiate tissue plasminogen activator-induced fibrinogen proteolysis.
Weitz JI; Leslie B; Ginsberg J
J Clin Invest; 1991 Mar; 87(3):1082-90. PubMed ID: 1900308
[TBL] [Abstract][Full Text] [Related]
48. Remaining perspectives of mutant and chimeric plasminogen activators.
Lijnen HR; Collen D
Ann N Y Acad Sci; 1992 Dec; 667():357-64. PubMed ID: 1309056
[TBL] [Abstract][Full Text] [Related]
49. Variable Resistance to Plasminogen Activator Initiated Fibrinolysis for Intermediate-Risk Pulmonary Embolism.
Stubblefield WB; Alves NJ; Rondina MT; Kline JA
PLoS One; 2016; 11(2):e0148747. PubMed ID: 26866684
[TBL] [Abstract][Full Text] [Related]
50. Disintegration and reorganization of fibrin networks during tissue-type plasminogen activator-induced clot lysis.
Meh DA; Mosesson MW; DiOrio JP; Siebenlist KR; Hernandez I; Amrani DL; Stojanovich L
Blood Coagul Fibrinolysis; 2001 Dec; 12(8):627-37. PubMed ID: 11734662
[TBL] [Abstract][Full Text] [Related]
51. tPA Point Mutation at Autolysis Loop Enhances Resistance to PAI-1 Inhibition and Catalytic Activity.
Peng S; Xue G; Chen S; Chen Z; Yuan C; Li J; Huang M
Thromb Haemost; 2019 Jan; 119(1):77-86. PubMed ID: 30597502
[TBL] [Abstract][Full Text] [Related]
52. Blood clearance and activity of erythrocyte-coupled fibrinolytics.
Ganguly K; Krasik T; Medinilla S; Bdeir K; Cines DB; Muzykantov VR; Murciano JC
J Pharmacol Exp Ther; 2005 Mar; 312(3):1106-13. PubMed ID: 15525799
[TBL] [Abstract][Full Text] [Related]
53. Type 1 plasminogen activator inhibitor binds to fibrin via vitronectin.
Podor TJ; Peterson CB; Lawrence DA; Stefansson S; Shaughnessy SG; Foulon DM; Butcher M; Weitz JI
J Biol Chem; 2000 Jun; 275(26):19788-94. PubMed ID: 10764803
[TBL] [Abstract][Full Text] [Related]
54. Identification of the mechanism responsible for the increased fibrin specificity of TNK-tissue plasminogen activator relative to tissue plasminogen activator.
Stewart RJ; Fredenburgh JC; Leslie BA; Keyt BA; Rischke JA; Weitz JI
J Biol Chem; 2000 Apr; 275(14):10112-20. PubMed ID: 10744692
[TBL] [Abstract][Full Text] [Related]
55. Effect of hirudin on tissue plasminogen activator induced clot lysis.
Electricwala A; Atkinson T
Blood Coagul Fibrinolysis; 1990 Aug; 1(3):267-71. PubMed ID: 2129413
[TBL] [Abstract][Full Text] [Related]
56. The significance of fibrin binding by plasminogen activator inhibitor 1 for the mechanism of tissue-type plasminogen activator-mediated fibrinolysis.
Stringer HA; Pannekoek H
J Biol Chem; 1995 May; 270(19):11205-8. PubMed ID: 7744752
[TBL] [Abstract][Full Text] [Related]
57. [Measurements of plasmin-alpha 2 plasmin inhibitor complex and FDP.D dimer levels in the fibrinolytic therapy of acute pulmonary thromboembolism].
Yamasawa F; Hasegawa N; Asano K; Sayama K; Fujita H; Urano T; Aoki T; Ishizaka A; Kanazawa M; Kawashiro T
Kokyu To Junkan; 1992 Jul; 40(7):685-90. PubMed ID: 1387724
[TBL] [Abstract][Full Text] [Related]
58. Adenovirus-mediated transfer of tissue-type plasminogen activator augments thrombolysis in tissue-type plasminogen activator-deficient and plasminogen activator inhibitor-1-overexpressing mice.
Carmeliet P; Stassen JM; Van Vlaenderen I; Meidell RS; Collen D; Gerard RD
Blood; 1997 Aug; 90(4):1527-34. PubMed ID: 9269770
[TBL] [Abstract][Full Text] [Related]
59. Direct microscopic monitoring of initial and dynamic clot lysis using plasmin or rt-PA in an in vitro flow system.
Bizjak N; Bajd F; Vidmar J; Blinc A; Perme MP; Marder VJ; Novokhatny V; Serša I
Thromb Res; 2014 May; 133(5):908-13. PubMed ID: 24613694
[TBL] [Abstract][Full Text] [Related]
60. Interaction between plasminogen activator inhibitor type 1 (PAI-1) bound to fibrin and either tissue-type plasminogen activator (t-PA) or urokinase-type plasminogen activator (u-PA). Binding of t-PA/PAI-1 complexes to fibrin mediated by both the finger and the kringle-2 domain of t-PA.
Wagner OF; de Vries C; Hohmann C; Veerman H; Pannekoek H
J Clin Invest; 1989 Aug; 84(2):647-55. PubMed ID: 2503541
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
